Dr. Seymour Fein is the founder and managing partner of Fein & Associates, LLC, a consulting firm providing multi-disciplinary drug development services to the biopharmaceutical industry. Dr. Fein brings over 35 years of experience working for large and small biopharmaceutical companies including Hoffmann-LaRoche, Bayer and Ohmeda. He has had success as an entrepreneur founding or serving as CEO of several small pharmaceutical companies such as ChiRhoClin, Serenity Pharmaceuticals and Westhaven Therapeutics. Dr. Fein has led clinical research teams which have successfully developed and gained FDA approvals for close to 20 investigational drug products including recombinant interferon alfa for several cancer indications, calcium channel blockers for cardiac and neurological indications, synthetic porcine and human secretins for gastroenterologic and oncologic indications, drugs for reproductive endocrinology including Repronex and Follistim and Noctiva for nocturia. More recently Dr. Fein has served as consulting medical director or CMO for companies developing oncolytic viruses, anti-sense oligonucleotides, cancer vaccines and allogeneic CAR T-cell therapy for cancer indications. Dr. Fein completed his residency in internal medicine at Dartmouth Medical Center and a 3-year fellowship in hematology-oncology and Beth-Israel Deaconess Medical Center in Boston. Dr. Fein has joined Persevere Therapeutics to serve as a fractional Chief Medical Officer.